{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T01:00:28Z","timestamp":1786410028384,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3,1]]},"DOI":"10.2146\/ajhp100394","type":"journal-article","created":{"date-parts":[[2011,2,18]],"date-time":"2011-02-18T04:45:39Z","timestamp":1298004339000},"page":"389-398","source":"Crossref","is-referenced-by-count":36,"title":["Febuxostat for treatment of chronic gout"],"prefix":"10.1093","volume":"68","author":[{"given":"Charnelda L.","family":"Gray","sequence":"first","affiliation":[{"name":"Kaiser Permanente of Georgia, Atlanta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafesa E.","family":"Walters-Smith","sequence":"additional","affiliation":[{"name":"Kaiser Permanente of Georgia, Tucker"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041105533540600_b1-0680389","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"key\n\t\t\t\t2019041105533540600_b2-0680389","first-page":"37","article-title":"Febuxostat (Uloric) for chronic treatment of gout","volume":"51","year":"2009","journal-title":"Med Lett Drugs Ther"},{"key":"key\n\t\t\t\t2019041105533540600_b3-0680389","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1081\/NCN-200027372","article-title":"Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in health volunteers","volume":"23","author":"Becker","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"(suppl 1)","key":"key\n\t\t\t\t2019041105533540600_b4-0680389","first-page":"S1","article-title":"A concise history of gout and hyperuricemia and their treatment","volume":"8","author":"Nuki","year":"2006","journal-title":"Arthritis Res"},{"key":"key\n\t\t\t\t2019041105533540600_b5-0680389","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041105533540600_b6-0680389","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ajkd.2002.33911","article-title":"The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988\u20131994","volume":"40","author":"Kramer","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041105533540600_b7-0680389","unstructured":"Adams PF Henderson GE Marano MA . Current estimates from the National Health Interview Survey, 1996. www.cdc.gov\/nchs\/data\/series\/sr_10\/sr10_200.pdf (accessed 2010 Oct 13)."},{"key":"key\n\t\t\t\t2019041105533540600_b8-0680389","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1742-1241.2006.01104.x","article-title":"Gout assessment questionnaire: initial results of reliability, validity and responsiveness","volume":"60","author":"Colwell","year":"2006","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t2019041105533540600_b9-0680389","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041105533540600_b10-0680389","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: a twenty-eight day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041105533540600_b11-0680389","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041105533540600_b12-0680389","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041105533540600_b13-0680389","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041105533540600_b14-0680389","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/0091270008322035","article-title":"The effect of age and gender on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase","volume":"48","author":"Khosravan","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041105533540600_b15-0680389","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/14656560902950742","article-title":"Gout\u2014what are the treatment options?","volume":"10","author":"Schlesinger","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"(suppl)","key":"key\n\t\t\t\t2019041105533540600_b16-0680389","first-page":"S443","article-title":"Diagnosis of gout: clinical, laboratory and radiologic findings","volume":"11","author":"Schlesinger","year":"2005","journal-title":"Am J Manag Care"},{"key":"key\n\t\t\t\t2019041105533540600_b17-0680389","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.clindermatol.2006.07.015","article-title":"Metabolic diseases: gout","volume":"24","author":"Falasca","year":"2006","journal-title":"Clin Dermatol"},{"key":"key\n\t\t\t\t2019041105533540600_b18-0680389","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.rdc.2005.10.003","article-title":"Newer therapeutic approaches: gout","volume":"32","author":"Schumacher","year":"2006","journal-title":"Rheum Dis Clin North Am"},{"key":"key\n\t\t\t\t2019041105533540600_b19-0680389","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00007890-200108270-00019","article-title":"Uricosuric effect of losartan in patients with renal transplants","volume":"72","author":"Kamper","year":"2001","journal-title":"Transplantation"},{"key":"key\n\t\t\t\t2019041105533540600_b20-0680389","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/keg103","article-title":"Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout","volume":"42","author":"Feher","year":"2003","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019041105533540600_b21-0680389","doi-asserted-by":"crossref","first-page":"385","DOI":"10.7326\/0003-4819-84-4-385","article-title":"Ascorbic acid-induced uricosuria. A consequence of megavitamin therapy","volume":"84","author":"Stein","year":"1976","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041105533540600_b22-0680389","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","article-title":"The management of gout","volume":"334","author":"Emmerson","year":"1996","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105533540600_b23-0680389","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1445-5994.2007.01315.x","article-title":"Emerging therapies in long-term management of hyperuricaemia and gout","volume":"37","author":"Stamp","year":"2007","journal-title":"Int Med J"},{"key":"key\n\t\t\t\t2019041105533540600_b24-0680389","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1081\/NCN-200027381","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase\/xanthine dehydrogenase (NPSIXO) in patients with gout and\/or hyperuricemia","volume":"23","author":"Komoriya","year":"2004","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"key\n\t\t\t\t2019041105533540600_b25-0680389","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0014-2999(93)90201-R","article-title":"Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents","volume":"241","author":"Osada","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t2019041105533540600_b26-0680389","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1345\/aph.1H121","article-title":"Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout","volume":"40","author":"Bruce","year":"2006","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041105533540600_b27-0680389","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/13543784.14.7.893","article-title":"Febuxostat: a non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout","volume":"14","author":"Schumacher","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"key\n\t\t\t\t2019041105533540600_b28-0680389","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/00498250801956350","article-title":"In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition","volume":"38","author":"Mukoyoshi","year":"2008","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t2019041105533540600_b29-0680389","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","article-title":"Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects","volume":"45","author":"Khosravan","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041105533540600_b30-0680389","volume-title":"Uloric (febuxostat) prescribing information","year":"2009"},{"key":"key\n\t\t\t\t2019041105533540600_b31-0680389","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"key\n\t\t\t\t2019041105533540600_b32-0680389","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0091270005282634","article-title":"The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase","volume":"46","author":"Khosravan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041105533540600_b33-0680389","doi-asserted-by":"crossref","first-page":"P43","DOI":"10.1016\/j.clpt.2004.12.059","article-title":"Effect of febuxostat on pharmacokinetics of desipramine, a CYP2D6 substrate in healthy subjects","volume":"77","author":"Khosravan","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2019041105533540600_b34-0680389","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019041105533540600_b35-0680389","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105533540600_b36-0680389","first-page":"1532","article-title":"Febuxostat versus allopurinol for gout","volume":"354; 14","author":"Lustberg","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105533540600_b37-0680389","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041105533540600_b38-0680389","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res"},{"key":"key\n\t\t\t\t2019041105533540600_b39-0680389","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019041105533540600_b40-0680389","unstructured":"ClinicalTrials.gov. Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities (CARES). www.clinicaltrials.gov\/ct2\/show\/NCT01101035 (accessed 2010 Nov 23)."},{"key":"key\n\t\t\t\t2019041105533540600_b41-0680389","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"key\n\t\t\t\t2019041105533540600_b42-0680389","first-page":"191,686,794","year":"2010","journal-title":"Red book 2010"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/5\/389\/28348998\/ajhp0389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T16:44:12Z","timestamp":1560012252000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/5\/389\/5129684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,1]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,3,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100394","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,3,1]]},"published":{"date-parts":[[2011,3,1]]}}}